Lausanne, Switzerland
Oculis, founded in 2017, is a global biopharmaceutical company, publicly listed as Nasdaq: OCS and XICE: OCS. With headquarters in Switzerland and operations in the U.S. and Iceland, the company is focused on saving sight and enhancing eye care worldwide.
Its innovative pipeline features multiple promising candidates, such as OCS-01 for diabetic macular edema and post-cataract surgery inflammation and pain, OCS-02 for dry eye disease and non-infectious anterior uveitis, and OCS-05 for acute optic neuritis. These topical eye drops signify a shift towards non-invasive ophthalmic treatments.
Oculis received a substantial $59.00M in post-IPO equity investment as of April 11, 2024. This support underscores confidence in its visionary approach and seasoned management team. With backing from leading international healthcare investors, Oculis is poised to significantly impact the Biotechnology, Health Care, and Pharmaceutical industries.
